NeoGenomics (NasdaqCM:NEO) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsPriya Vedaraman - SVP of FinanceJeff Sherman - CFOTony Zook - CEOWarren Stone - COOConference Call ParticipantsNone - AnalystNone - AnalystNone - AnalystMason Carrico - Research AnalystAndrew Brackmann - AnalystYuko Oku - AnalystDavid Westerberg - AnalystPuneet Souda - AnalystNone - AnalystNone - AnalystPriya VedaramanGood morning everyone and welcome to the NeoGenomics third quarter 2025 financial results call ...

Oct 28, 2025 7:05 AM Eastern Daylight Time NeoGenomics Reports Third Quarter 2025 Results Share Third quarter total revenue increased 12% YoY to $188 millionClinical revenue grew 18%, or 15% excluding the Pathline acquisitionNGS revenue increased 24% YoY and now accounts for nearly one- third of clinical revenueRe-affirming full-year guidance for revenue, net loss and adjusted EBITDA FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the "Company†), a leading provider of oncology diagnost ...